AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04704206 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Children will perform activities on interactive tablet
Description: The main difference between the types of interventions is the mode of use and the level of interactivity of the interactive media, where the AIMG actively performs activities, that is, there is user interaction with the equipment through touch or verbal response and the performance of activities like rotating an object, dragging and zooming. PIMG is not the same, the user is just a spectator, having contact with the equipment only when switching on / off, choosing the content, performing activities such as increasing / decreasing the volume and touching certain specific objects such as giving play / pause . Both groups will have a total of 48 intervention sessions.
Study NCT06105658 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Unrelated umbilical cord blood
Description: The requirements of unrelated umbilical cord blood: recipient-donor HLA match is 0-3/10, same blood type.
Study NCT06105658 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Patients will be treated with Venetoclax (100 mg on day 1, 200 mg on day 2 and 400 mg on days 3 to 21)
Study NCT06105658 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decetabine
Description: Patients will be treated with Decetabine (20mg/m\^2/d on days 1 to 5) or Azacitidine (75mg/m\^2/d on days 1 to 7)
Study NCT06105658 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Patients will be treated with Decetabine (20mg/m\^2/d on days 1 to 5) or Azacitidine (75mg/m\^2/d on days 1 to 7)
Study NCT05117021 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caudal Epidural Block using 0.25% plain bupivacaine dose 1 ml / kg and Ultrasound Guided Transversus Abdominis Plane Block using 0.25% plain bupivacaine dose 0.5 ml / kg
Description: Caudal Epidural Block and Ultrasound Guided Transversus Abdominis Plane Block using 0.25% plain bupivacaine
Study NCT05561465 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pterygomaxillary disjunction with interposition Y-shape plate
Description: All patients will be treated under general anesthesia. The pterygoid plate will be fractured, pried up, and pushed backward. A Y-shape plate will be fixed to the lateral maxillary surface with its vertical limb and the other two limbs are turned to fit into the retro maxillary space preventing the reattachment of the fractured pterygoid plate
Study NCT06461728 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: a new prototye device that heat and activate sodium hyochlorite (Aseptico)
Description: endoactivator : it is a sonic activator device
Study NCT06461728 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: a new prototye device that heat and activate sodium hyochlorite (Aseptico)
Description: endoactivator : it is a sonic activator device
Study NCT06355115 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cefazolin 1000 MG Injection
Description: Cefazolin 1000 mg given intravenously
Study NCT06355115 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cefazolin 1000 MG Injection
Description: Cefazolin 1000 mg given intravenously
Study NCT04152603 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BRIEF Educational Module
Description: The BRIEF Educational Module for research recruitment team members is intended to teach evidence-based approaches to improving participant experiences with research recruitment. It has three components: (1) asynchronous pre-work, including multimedia materials and an individual worksheet (approx. 30 min); (2) one synchronous in-person (or virtual if necessary) session, including didactics, discussions, and practice scenarios (approx. 90 min); and (3) an asynchronous, individual follow-up phone call to review individual questions (approx. 15 min).
Study NCT06490263 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimental: Mulberry Twig Alkaloids Tablets 126 mg single dose in healthy subjects
Description: Part One: Administered by chewing with meals or swallowing after meals, with a dosage of 126 milligrams, given as a single dose only.
Study NCT06490263 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mulberry Twig Alkaloids Tablets with single dose in healthy subjects
Description: Parts Two: Administered by swallowing after meals with four distinct dosage groups.
Study NCT06490263 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mulberry Twig Alkaloids Tablets with multiple dose in healthy subjects
Description: Part Three: Administered by swallowing after meals with two distinct dosage groups, taken three times daily.
Study NCT06490263 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mulberry Twig Alkaloids Tablets with multiple dose in overweight or obese subjects
Description: Part Three: Administered by swallowing after meals with two distinct dosage groups, taken three times daily.
Study NCT04537000 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: clinical condition score
Description: A score is firstly identified using a clinical condition scale including the concentration of inspired oxygen to maintain the percutaneous oxygen saturation (SPO2)≧95%, the fusion rate of catecholamine drugs to maintain normal blood pressure, the nasopharyngeal temperature and the oxygen saturation of central venous blood. The score was graded as 0, 1 and 2 points according to the patient's clinical condition. The score identified from the scale plus 7 finally makes the clinical condition score. If the score is higher than 10, it will be replaced with 10. That is to say, the highest clinical condition score is 10. If the clinical condition score≦Hb, blood red cell transfusion will not be started. If the clinical condition score>Hb, blood red cell transfusion will be started, and the volume will be calculated using the following formulation, transfusion volume(ml)=(clinical condition score - Hb)\*body weight \*5.
Study NCT05159700 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRJ1-3024
Description: PRJ1-3024 is provided as capsules and is administered orally once a day.
Study NCT06414356 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Ketamine will be placed in 250 mL normal saline and infused at a rate of 62.5 mL/hr. Participants will receive intravenous infusions of ketamine for 4 hours each day in diminishing number of dosing events per week for the full 24-week infusion regime in an outpatient setting. (ketamine 0.5 mg/kg IBW/hr)
Study NCT06414356 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium sulfate
Description: Magnesium sulfate 3 grams will be diluted into 250 mL normal saline and infused at a rate of 62.5 mL/hr (over 4 hours until the entire contents are infused and then flushed with 20 mL of normal saline). The Mg only group will be randomly assigned to one of the treatment groups (moderate dose ketamine, or moderate dose ketamine +Mg) after 2 weeks and complete the full 24-week infusion treatment regime of the randomly selected treatment group in an outpatient setting.
Study NCT06414356 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine + Magnesium sulfate
Description: Participants will receive intravenous infusions of ketamine and magnesium sulfate in combination. Ketamine will be placed in 250 mL normal saline and infused at a rate of 62.5 mL/hr Participants will receive intravenous infusions of ketamine and magnesium sulfate for 4 hours each day in diminishing number of dosing events per week for the full 24-week infusion regime in an outpatient setting. (Ketamine 0.5 mg/kg IBW/hr + magnesium sulfate 3 grams diluted into 250 mL normal saline)
Study NCT04642404 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epidiolex 100 mg/mL Oral Solution
Description: Cannabidiol (CBD): is the primary non-psychoactive and non-addictive compound in cannabis, has already shown potential in treating pain such as arthritis, neuropathic, cancer and chronic pain
Study NCT04642404 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo drug will be a solution with the same taste, texture and color as the drug.
Study NCT04637555 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sacubitril/valsartan
Description: LCZ696 (sacubitril/valsartan) tablet will be available in 24/26 mg, 49/51 mg and 97/103 mg, respectively
Study NCT05489666 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Nature Made Vitamin D3 5,000 IU, 125mcg
Description: Taking a 5,000 IU oral supplement of Vitamin D3, daily, for 8 weeks, may improve strength performance in women who have and are continuing a resistance trained workout regimen. After blood vitamin D levels have been raised to an optimal range, a lower dosage may be assigned as needed from 5,000 IU per day to 1,000-2,000 IU per day.
Study NCT05489666 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Resistance trained women may not improve their strength performance with low levels of vitamin D in the blood.
Study NCT02814747 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: quantitive study: 500 patients likely to be candidates for HTS
Study NCT02814747 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: qualitative study: 30 patients who have benefited from HTS
Study NCT04882930 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Functional Near-Infrared Spectroscopy (fNIRS)
Description: All participants will undergo Functional Near-Infrared Spectroscopy (fNIRS). The hemodynamic response in CPF will be measured using an Octomon+ system (Artinis). Eight emission and two detector probes will be arranged on the participant's forehead.
Study NCT06282965 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Angiotensin (1-7)
Description: The drug will be dissolved in 0.9% USP/NF grade sterile for injection saline (NaCl) and prepared in a concentration that aligns with the participant's weight.
Study NCT06282965 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sterile saline
Description: Sterile solution of 0.9% NaCl in water.
Study NCT05482659 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health education on healthy nutrition and regular physical activity based on the transtheoretic model
Description: An announcement was made by visiting all the faculties at Nuh Naci Yazgan University, stating the content of the research and the duration of the research. Among the volunteer students, students who met the inclusion criteria were included in the study. Afterwards, the students were assigned to the groups by the statistician using a simple randomization method. As a result of the pre-test, it was determined which change stage each student was in according to the Transtheoretic model (TTM). The students were not given information about which group they were in and what stage they were in according to TTM. Health education was given to university students once a week by online education method and it took 4 weeks-30 days to complete the research. The average duration of the health education given to each student is 30-45 minutes. When the training process was over, the post-test questions were sent to the students by the online survey method.
Study NCT05656833 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Fractional 1927nm Low-Powered Diode Laser
Description: Clear \& Brilliant Permea® Laser used on the side of the face randomized to receive laser
Study NCT05656833 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Topical Cysteamine
Description: Topical Cysteamine cream will be used on the entire face.
Study NCT05050396 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cooled versus thermocoagulant Radiofrequency Ablation in pain relief of knee osteoarthritis
Description: Radiofrequency (RF) ablation, or modulation of the sensory innervation surrounding the knee, specifically the genicular nerves (GNs), has emerged as a therapeutic option to treat chronic knee OA pain for patients who are unresponsive to conservative treatments or are unsuitable candidates for total knee arthroplasty (TKA). \[16, 17\] Similar to conventional RFA, water-cooled radiofrequency (CRF) ablation is a novel technology that utilizes thermal ablative mechanisms; however, CRF gives the ability to create a greater local neuronal lesion to increase the changes of effective denervation \[20\]
Study NCT05063851 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Memantine Hydrochloride Tablets
Description: The recommended starting dose of memantine hydrochloride/placebo is 5 mg once daily. The dose should be increased in 5 mg increments to 10 mg/day (5 mg twice daily), 15 mg/day (5 mg and 10 mg as separate doses), and 20 mg/day (10 mg twice daily). The minimum recommended interval between dose increases is one week. The dosage shown to be effective in controlled clinical trials is 20 mg/day.
Study NCT05063851 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The recommended starting dose of memantine hydrochloride/placebo is 5 mg once daily. The dose should be increased in 5 mg increments to 10 mg/day (5 mg twice daily), 15 mg/day (5 mg and 10 mg as separate doses), and 20 mg/day (10 mg twice daily). The minimum recommended interval between dose increases is one week. The dosage shown to be effective in controlled clinical trials is 20 mg/day.
Study NCT05393739 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Theta burst transcranial magnetic stimulation (TBS) procedure
Description: The procedure includes determining the specific occipital point at which place the stimulation coil; this corresponds to the area where magnetic stimulation is most capable of inducing phosphenes or transient visual phenomena. The phosphenes are directly induced by stimulation of the visual cortex and their presence indicates that the magnetic stimulation is in the correct location. The subjects would wear a personalized swimming cap with the determined area for stimulation marked on it. The major differences between iTBS and cTBS are the frequency and interval of stimulus.
Study NCT05393739 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Theta burst transcranial magnetic stimulation (TBS) procedure
Description: The procedure includes determining the specific occipital point at which place the stimulation coil; this corresponds to the area where magnetic stimulation is most capable of inducing phosphenes or transient visual phenomena. The phosphenes are directly induced by stimulation of the visual cortex and their presence indicates that the magnetic stimulation is in the correct location. The subjects would wear a personalized swimming cap with the determined area for stimulation marked on it. The major differences between iTBS and cTBS are the frequency and interval of stimulus.
Study NCT05410262 — intervention group
Intervention type: OTHER
Intervention: Evaluation of CT images
Description: A helicoidal CT scanner will be used (Aquilion CXL, Toshiba, Japan), with AIDR 3D technique (Adaptive Iterative Dose Reduction 3D) in order to minimize exposure to X-rays. Two complete thorax CT scans will be performed, one of them in expiratory pause (PEEP) and the other in inspiratory pause (PPlat). Esophageal pressure shall be measured (FluxMed GrT, Argentina) and transpulmonary pressure will be calculated at the end of inspiration (Ppl-insp) and expiration (Ppl-exp).
Study NCT05045170 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Influence of propofol sedation on memory consolidation and 'working memory'
Description: Spinal anesthesia is performed by anesthesiologist. Memory testing is conducted immediately prior to propofol sedation (stage 1), 5-10 minutes after the start of propofol sedation (stage 2), 10 minutes after propofol sedation is finished and consciousness is restored (stage 3). Five emotionally neutral words are heard by the patients twice at each stage to assess the impact of sedation on memory consolidation. The patients repeat the memorized words after each audition. To assess the effect of sedation on the 'working memory', anesthesiologist asked the patient to remember and reproduce the memorized words five minutes after learning in the second stage. Approximately, 24 hours after the end of anesthesia, recall and recognition of the experimental words are tested. The number of words in recall and recognition testing is recorded by researcher.
Study NCT05045170 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Influence of dexmedetomidine sedation on memory consolidation and 'working memory'
Description: Spinal anesthesia is performed by anesthesiologist. Memory testing is conducted immediately prior to dexmedetomidine sedation (stage 1), 5-10 minutes after the start of dexmedetomidine sedation (stage 2), 10 minutes after dexmedetomidine sedation is finished and consciousness is restored (stage 3). Five emotionally neutral words are heard by the patients twice at each stage to assess the impact of sedation on memory consolidation. The patients repeat the memorized words after each audition. To assess the effect of sedation on the 'working memory', anesthesiologist asked the patient to remember and reproduce the memorized words five minutes after learning in the second stage. Approximately, 24 hours after the end of anesthesia, recall and recognition of the experimental words are tested. The number of words in recall and recognition testing is recorded by researcher.
Study NCT05045170 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Influence of spinal anesthesia on memory consolidation and 'working memory'
Description: Spinal anesthesia is performed by anesthesiologist. Memory testing is conducted immediately prior to operation (stage 1), 5-10 minutes after the start of operation (stage 2), 10 minutes before the end of operation (stage 3). Five emotionally neutral words are heard by the patients twice at each stage to assess the impact of sedation on memory consolidation. The patients repeat the memorized words after each audition. To assess the effect of sedation on the 'working memory', anesthesiologist asked the patient to remember and reproduce the memorized words five minutes after learning in the second stage. Approximately, 24 hours after the end of anesthesia, recall and recognition of the experimental words are tested. The number of words in recall and recognition testing is recorded by researcher.
Study NCT05893433 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bedside cycling
Description: participants receive daily cycling once the patient is relatively stable by weaning off the ventilator and off the require inotropic support and continued to the discharge from the hospital.~Duration progression if the following conditions are reached:~1. Initially increase the duration by up to15 min of low exercise time and then increase the intensity after the patient can complete 15- 20 min.~2. Complete 15min with a medially stable condition gradually until reaching 20 minutes besides the routine physical therapy protocol of breathing exercises, coughing techniques, chest wall vibrations, and mobilization is common during the first postoperative days, The two most frequently used breathing techniques were deep breathing exercises and incentive spirometry and the medical treatment.
Study NCT05893433 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: control
Description: the routine physical therapy protocol of breathing exercises, coughing techniques, chest wall vibrations, and mobilization is common during the first postoperative days, The two most frequently used breathing techniques were deep breathing exercises and incentive spirometry and the medical treatment.
Study NCT06390787 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metoclopramide and Vitamin B6
Description: We gave a combination of vitamin B6 (pyridoxine) and metoclopramide as a treatment for managing nausea and vomiting.
Study NCT06390787 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin B6
Description: We gave only vitamin B6 (pyridoxine) as a treatment for managing nausea and vomiting.
Study NCT06390787 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ondansetron
Description: We gave only Zofran as a treatment for managing nausea and vomiting.
Study NCT06390787 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metoclopramide
Description: We gave only Metoclopramide as a treatment for managing nausea and vomiting.
Study NCT04912895 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: PneumoniaCheck
Description: Participants are asked to do 5 sets of 10 coughs, with at least 15 minutes between sets, into the PneumoniaCheck device.
Study NCT04912895 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PneumoniaCheck
Description: Participants are asked to do 5 sets of 10 coughs, with at least 15 minutes between sets, into the PneumoniaCheck device.
Study NCT04912895 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PneumoniaCheck
Description: Participants are asked to do 5 sets of 10 coughs, with at least 15 minutes between sets, into the PneumoniaCheck device.
Study NCT06376110 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topical Antioxidant Serum
Description: An oil-free vitamin C serum for oily skin and blemish-prone skin that delivers advanced environmental protection, reduces oiliness, refines skin texture, and visibly improves skin clarity and fine lines.
Study NCT06376110 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: AviClear Laser
Description: The AviClear (1726nm) laser is FDA-cleared for use on mild to severe inflammatory acne, with a recommended treatment course comprised of 3 laser procedures each one month apart.
Study NCT05568147 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin tablet
Description: When patients are randomized into the intervention group, they will receive aspirin at the dosage of 100mg orally once every day.
Study NCT05568147 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: When patients are randomized into the placebo group, they will receive placebo orally once a day.